Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Carbon Monoxide in Kidney Transplant
NCT00531856Phase 2Withdrawn
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Aug 2007
- Primary completion
- Aug 2011
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Carbon monoxide in delayed graft function (DGF) (2 arms), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Safety and Tolerability of Inhaled Carbon Monoxide at 28 days. Planned start Aug 2007; status: withdrawn.
02
Drugs
Carbon monoxide
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on NCT00531856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00531856.